Publication: Benefit of double contrast MRI in diagnosis of hepatocellular carcinoma in patients with chronic liver diseases
Issued Date
2014-01-01
Resource Type
ISSN
01252208
Other identifier(s)
2-s2.0-84902777414
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of the Medical Association of Thailand. Vol.97, No.5 (2014), 540-547
Suggested Citation
Wanwarang Teerasamit, Pairash Saiviroonporn, Ananya Pongpaibul, Pornpim Korpraphong Benefit of double contrast MRI in diagnosis of hepatocellular carcinoma in patients with chronic liver diseases. Journal of the Medical Association of Thailand. Vol.97, No.5 (2014), 540-547. Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/34439
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Benefit of double contrast MRI in diagnosis of hepatocellular carcinoma in patients with chronic liver diseases
Other Contributor(s)
Abstract
Objective: To assess the benefit on diagnosis of hepatocellular carcinoma (HCC) in patients with chronic liver disease or cirrhosis with double contrast MR imaging compared to the routine gadolinium-based MR imaging. Material and Method: Seventy-one consecutive patients with cirrhosis or chronic hepatitis underwent multiphase, gadoliniumenhanced liver MRI examination and sequentially superparamagnetic iron oxide (SPIO)-enhanced images. The presence signal intensities of lesions on non-contrast sequences, dynamic gadolinium-enhanced images and delayed 10-min post-SPIO T2*-weighted images were recorded. Results: Among 27 patients, 15 HCCs from 12 patients were diagnosed by surgical (n = 7) and non-surgical (n = 8) proofs. The overall sensitivity, specificity, positive predictive value, and negative predictive value of double contrast-enhanced images in 12 patients were 83.3% (95% CI: 58.5, 96.2), 33.3% (95% CI: 5.4, 88.4), 88.2% (95% CI: 63.5, 98.2), and 25% (95% CI: 4.1, 79.6) and these of gadolinium-enhanced images were 72.2% (95% CI: 46.5, 90.2), 33.3% (95% CI: 5.4, 88.4), 86.6% (95% CI: 59.5, 97.9), and 16.6% (95% CI: 2.7, 63.9), respectively. There were two benign hepatic nodules (1 adenoma, 1 dysplastic nodule) suspected as HCCs on MR images and two surgically proven-HCCs, invisible on gadolinium-enhanced images, detected as defect on only delayed 10-min post-SPIO T2*-weighted images. Conclusion: SPIO-enhanced images in double contrast-enhanced MR imaging had an additional value on HCC detection, compared to gadolinium-enhanced MR imaging, in patients with chronic liver disease or cirrhosis.